Bio-Rad anti-ranibizumab antibodies

Bio-Rad Laboratories has launched a range of recombinant monoclonal anti-ranibizumab antibodies that are highly specific for the monoclonal antibody drug ranibizumab (Lucentis) or the complex of ranibizumab with its target, vascular endothelial growth factor A (VEGF-A).

Ranibizumab is used for the treatment of wet age-related macular degeneration (AMD), a common form of age-related vision loss, and for macular edema and diabetic retinopathy. The anti-ranibizumab antibodies are inhibitory, non-inhibitory and drug-target complex specific antibodies and designed for use in pharmacokinetic (PK) and immunogenicity assays for ranibizumab and biosimilars.

Ranibizumab is a Fab fragment drug and is present at low levels in patient samples, which presents challenges for PK assay design and sensitivity. Bio-Rad’s high-affinity ranibizumab-VEGF complex specific antibody overcomes those challenges by enabling the development of a PK antigen capture assay to measure free drug.

The anti-idiotypic antibodies are generated using Human Combinatorial Antibody Library (HuCAL) and CysDisplay, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures a consistent and secure supply.

The anti-ranibizumab antibodies are approved for in vitro research and for commercial applications of in vitro testing services that support preclinical and clinical drug and biosimilar development and patient monitoring.